S. Jalkanen

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph+CD34+CD38neg) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

S. Mustjoki, K. Porkka, T. Lundán, 2010, Leukemia.

Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.

S. Mustjoki, K. Porkka, A. Kreutzman, 2011, Experimental hematology.

Somatic STAT3 mutations in large granular lymphocytic leukemia.

S. Mustjoki, O. Kallioniemi, K. Wennerberg, 2012, The New England journal of medicine.

Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients.

S. Mustjoki, S. Hautaniemi, Ville Rantanen, 2011, Experimental hematology.

Dasatinib Induces a Rapid, Dose-Controllable Mobilization of Cytotoxic Lymphocytes: A Novel Immunomodulatory Effect Associated with Prolonged Therapy Responses In Advanced Leukemia.

S. Mustjoki, S. Hautaniemi, F. Lee, 2010 .

LBA38 Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types

J. Koivunen, M. D. de Jonge, M. Karvonen, 2021, Annals of Oncology.

Polymorphism in IFNAR contributes to glucocorticoid response and outcome in ARDS and COVID-19

L. Elo, Nan Wang, K. Elima, 2022, medRxiv.

FlowAnd: Comprehensive Computational Framework for Flow Cytometry Data Analysis

Ping Chen, Sampsa Hautaniemi, Ville Rantanen, 2011 .